Trial ID or NCT#
NCT02032823
Status
NOT RECRUITING
Purpose
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Official Title
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Eligibility Criteria
Ages Eligible for Study: 18 Years to 130 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Allison W. Kurian, M.D., M.Sc.
Medical oncologist,
Breast specialist,
Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Melinda L. Telli, M.D.
Medical oncologist,
Breast specialist
Associate Professor of Medicine (Oncology)
Douglas W. Blayney
George W. Sledge Jr., M.D.
Medical oncologist,
Breast specialist
Adjunct Clinical Professor, Medicine - Oncology
Contact us to find out if this trial is right for you.
CONTACT
CCTO
(650) 498-7061
View on ClinicalTrials.gov